Silencing of GPR82 with Interference RNA Improved Metabolic Profiles in Rats with High Fructose Intake.


Journal

Journal of vascular research
ISSN: 1423-0135
Titre abrégé: J Vasc Res
Pays: Switzerland
ID NLM: 9206092

Informations de publication

Date de publication:
2020
Historique:
received: 27 10 2018
accepted: 06 05 2019
pubmed: 3 7 2019
medline: 10 9 2020
entrez: 3 7 2019
Statut: ppublish

Résumé

Metabolic syndrome (MS) is a clinical condition, constituted by alterations that lead to the onset of type II diabetes and cardiovascular disease. It has been reported that orphan G-protein-coupled receptor 82 (GPR82) participates in metabolic processes. The aim of this study was to evaluate the function of GPR82 in MS using a small interfering RNA (siRNA) against this receptor. We used Wistar rats of 10-12 weeks of age fed with a high-fructose solution (70%) for 9 weeks to induce MS. Subsequently, the rats were treated with an intrajugular dose of an siRNA against GPR82 and the effects were evaluated on day 3 and 7 after administration. On day 3 the siRNA had a transient effect on decreasing blood pressure and triglycerides and increasing high-density lipoprotein cholesterol, which recovered to the MS control on day 7. Decreased gene expressions of GPR82 mRNA in the aorta and heart were observed on day 3; moreover, decreased gene expression was maintained in the aorta on day 7. Therefore, we conclude that the orphan receptor GPR82 participates in the development of MS induced by fructose and the silencing of this receptor could ameliorate metabolic components.

Identifiants

pubmed: 31266033
pii: 000500781
doi: 10.1159/000500781
doi:

Substances chimiques

Dietary Carbohydrates 0
Receptors, G-Protein-Coupled 0
Triglycerides 0
Fructose 30237-26-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Rodrigo Romero-Nava (R)

Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Mexico City, Mexico.
Laboratorio de Investigación en Farmacología, Hospital Infantil de México Federico Gómez (HIMFG), Mexico City, Mexico.
Laboratorio de Farmacología, Departamento Ciencias de la Salud, Div. C.B.S., Universidad Autónoma Metropolitana, Unidad Iztapalapa, Mexico City, Mexico.

Karla Aidee Aguayo-Cerón (KA)

Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Mexico City, Mexico.

Armando Ruiz-Hernández (A)

Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Mexico City, Mexico.
Department of Pharmacology, School of Medicine, Autonomous University of Baja California, Mexicali, Mexico.

Fengyang Huang (F)

Laboratorio de Investigación en Farmacología, Hospital Infantil de México Federico Gómez (HIMFG), Mexico City, Mexico.

Enrique Hong (E)

Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados, Mexico City, Mexico.

Asdrubal Aguilera-Mendez (A)

Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás Hidalgo, Morelia, Mexico.

Santiago Villafaña Rauda (S)

Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Mexico City, Mexico, svillafana@ipn.mx.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH